Yasutaka Nakamura

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Clinical impact of opioid use in patients with urothelial carcinoma treated with pembrolizumab: a single center retrospective study.

Clinical impact of opioid use in patients with urothelial carcinoma treated with pembrolizumab: a single center retrospective study.

Journal: Immunotherapy

Published: July 15, 2026

Predictors of target initial teicoplanin trough concentration attainment in patients with hematological malignancies: a retrospective cohort study.

Predictors of target initial teicoplanin trough concentration attainment in patients with hematological malignancies: a retrospective cohort study.

Journal: Journal of pharmaceutical health care and sciences

Published: November 17, 2025

Evaluating the Impact of Linezolid Metabolites: PNU-142300 and PNU-142586 on the Development of Linezolid-Induced Thrombocytopenia in Adult Patients.

Evaluating the Impact of Linezolid Metabolites: PNU-142300 and PNU-142586 on the Development of Linezolid-Induced Thrombocytopenia in Adult Patients.

Journal: Journal of clinical pharmacology

Published: August 06, 2025

Efficacy of SGLT-2 Inhibitors in Preventing Cisplatin-induced Kidney Injury in Patients With Diabetes.

Efficacy of SGLT-2 Inhibitors in Preventing Cisplatin-induced Kidney Injury in Patients With Diabetes.

Journal: Anticancer research

Published: July 22, 2025

Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer.

Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer.

Journal: Immunotherapy

Published: April 14, 2025

Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors.

Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors.

Journal: International journal of clinical oncology

Published: February 03, 2025

Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor.

Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor.

Journal: International journal of clinical oncology

Published: April 30, 2024

Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study.

Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study.

Journal: Journal of pharmaceutical health care and sciences

Published: November 15, 2023

Analysis of Risk Factors for Febrile Neutropenia in Patients with Small-Cell Lung Cancer Receiving Carboplatin Plus Etoposide Therapy.

Analysis of Risk Factors for Febrile Neutropenia in Patients with Small-Cell Lung Cancer Receiving Carboplatin Plus Etoposide Therapy.

Journal: Oncology

Published: September 26, 2023

Analysis of Risk Factors for Infusion-Related Reactions Following Rituximab Administration in Patients with Desensitization before Renal Transplantation.

Analysis of Risk Factors for Infusion-Related Reactions Following Rituximab Administration in Patients with Desensitization before Renal Transplantation.

Journal: Biological & pharmaceutical bulletin

Published: September 04, 2023

Reliability and Validity of the Japanese Version of the Basel Assessment of Adherence to Immunosuppressive Medications Scale in Kidney Transplant Recipients.

Reliability and Validity of the Japanese Version of the Basel Assessment of Adherence to Immunosuppressive Medications Scale in Kidney Transplant Recipients.

Journal: Transplantation direct

Published: October 28, 2022

The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels.

The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels.

Journal: Biological & pharmaceutical bulletin

Published: October 02, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026